Top

Journal of Cardiovascular Translational Research

Published in:

Open Access 01-08-2017 | Original Article

Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy

Authors: Patricia P. Wadowski, Beate Eichelberger, Christoph W. Kopp, Joseph Pultar, Daniela Seidinger, Renate Koppensteiner, Irene M. Lang, Simon Panzer, Thomas Gremmel

Published in: Journal of Cardiovascular Translational Research | Issue 4/2017

Abstract

Disaggregation as the difference between maximal and final platelet aggregation by light transmission aggregometry indicates the stability of platelet aggregates. We evaluated the extent of disaggregation after platelet stimulation with adenosine diphosphate (ADP), arachidonic acid (AA), collagen, epinephrine, and thrombin receptor-activating peptide (TRAP)-6 in 323 patients on dual antiplatelet therapy with daily aspirin and clopidogrel (group 1), prasugrel (group 2), or ticagrelor (group 3) therapy. All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI. Significant differences between maximal and final platelet aggregation were observed with all agonists throughout the groups (all p<0.001). Disaggregation was highest using AA (clopidogrel 36.5%; prasugrel/ticagrelor 100%) and ADP (clopidogrel 21.7%; prasugrel/ticagrelor 100%). In contrast, low disaggregation was observed after platelet stimulation with collagen and TRAP-6 in clopidogrel-treated patients, and after platelet stimulation with collagen and epinephrine in prasugrel- and ticagrelor-treated patients. In conclusion, pathways of platelet activation that are not inhibited by standard antiplatelet therapy allow persisting platelet aggregation and may at least in part be responsible for adverse ischemic events.

Paniccia, R., Priora, R., Liotta, A. A., & Abbate, R. (2015). Platelet function tests: a comparative review. Vascular Health and Risk Management, 11, 133–148. doi:10.2147/VHRM.S44469.CrossRefPubMedPubMedCentral

Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2009). Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis, 101(2), 333–339.PubMed

Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2011). Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets, 22(3), 188–195. doi:10.3109/09537104.2010.543963.CrossRefPubMed

Born, G. V. (1962). Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 194, 927–929.CrossRefPubMed

O'Brien, J. R. (1961). The adhesiveness of native platelets and its prevention. Journal of Clinical Pathology, 14, 140–149.CrossRefPubMedPubMedCentral

Zhou, L., & Schmaier, A. H. (2005). Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. American Journal of Clinical Pathology, 123(2), 172–183.CrossRefPubMed

Cattaneo, M., Cerletti, C., Harrison, P., Hayward, C. P., Kenny, D., Nugent, D., et al. (2013). Recommendations for the standardization of light transmission aggregometry: A consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis. doi:10.1111/jth.12231.

Valenti, R., Marcucci, R., Capodanno, D., De Luca, G., Migliorini, A., Gori, A. M., et al. (2015). Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. Journal of Thrombosis and Thrombolysis, 40(1), 76–82. doi:10.1007/s11239-014-1159-1.CrossRefPubMed

Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y. H., Angiolillo, D. J., et al. (2013). Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. Journal of the American College of Cardiology, 62(24), 2261–2273. doi:10.1016/j.jacc.2013.07.101.CrossRefPubMed

10.

Lordkipanidze, M., Pharand, C., Palisaitis, D. A., Schampaert, E., & Diodati, J. G. (2009). Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thrombosis Research, 124(5), 546–553. doi:10.1016/j.thromres.2009.04.003.CrossRefPubMed

11.

Geisler, T., Langer, H., Wydymus, M., Gohring, K., Zurn, C., Bigalke, B., et al. (2006). Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 27(20), 2420–2425. doi:10.1093/eurheartj/ehl275.CrossRefPubMed

12.

Nocun, M., Golanski, J., Lapshina, E., Zavodnik, L., Dobaczewski, M., Kazmierczak, P., et al. (2006). Usefulness of whole blood aggregometry and its comparison with thromboxane generation assay in monitoring acetylsalicylic acid effectiveness—a multiparametric study in rats. Clinical Chemistry and Laboratory Medicine, 44(7), 853–862. doi:10.1515/CCLM.2006.157.CrossRefPubMed

13.

Savcic, M., Hauert, J., Bachmann, F., Wyld, P. J., Geudelin, B., & Cariou, R. (1999). Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Seminars in Thrombosis and Hemostasis, 25(Suppl 2), 15–19.PubMed

14.

Cadroy, Y., Bossavy, J. P., Thalamas, C., Sagnard, L., Sakariassen, K., & Boneu, B. (2000). Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation, 101(24), 2823–2828.CrossRefPubMed

15.

Floyd, C. N., Passacquale, G., Fau-Ferro, A., & Ferro, A. (2012). Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clinical Pharmacokinetics, 51(7), 429–442.CrossRefPubMed

16.

Michelson, A. D., Barnard, M. R., Krueger, L. A., Valeri, C. R., & Furman, M. I. (2001). Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation, 104(13), 1533–1537.CrossRefPubMed

17.

Gremmel, T., Michelson, A. D., & Frelinger 3rd, A. L. (2016). In vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets, 27(4), 308–316. doi:10.3109/09537104.2015.1095876.CrossRefPubMed

18.

Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357(20), 2001–2015. doi:10.1056/NEJMoa0706482.CrossRefPubMed

19.

Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 361(11), 1045–1057. doi:10.1056/NEJMoa0904327.CrossRefPubMed

20.

Yee, D. L., Sun, C. W., Bergeron, A. L., Dong, J. F., & Bray, P. F. (2005). Aggregometry detects platelet hyperreactivity in healthy individuals. Blood, 106(8), 2723–2729. doi:10.1182/blood-2005-03-1290.CrossRefPubMedPubMedCentral

21.

Jiang, X. L., Samant, S., Lesko, L. J., & Schmidt, S. (2015). Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clinical Pharmacokinetics, 54(2), 147–166. doi:10.1007/s40262-014-0230-6.CrossRefPubMed

22.

Schror, K. (1997). Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Seminars in Thrombosis and Hemostasis, 23(4), 349–356. doi:10.1055/s-2007-996108.CrossRefPubMed

23.

Storey, R. F., Angiolillo, D. J., Patil, S. B., Desai, B., Ecob, R., Husted, S., et al. (2010). Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient outcomes) PLATELET substudy. Journal of the American College of Cardiology, 56(18), 1456–1462. doi:10.1016/j.jacc.2010.03.100.CrossRefPubMed

24.

Sugidachi, A., Ohno, K., Ogawa, T., Jakubowski, J., Hashimoto, M., & Tomizawa, A. (2013). A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. British Journal of Pharmacology, 169(1), 82–89. doi:10.1111/bph.12108.CrossRefPubMedPubMedCentral

25.

Gremmel, T., & Panzer, S. (2011). Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis, 106(2), 211–218. doi:10.1160/TH11-03-0137.CrossRefPubMed

26.

Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., et al. (2004). Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109(25), 3171–3175. doi:10.1161/01.CIR.0000130846.46168.03.CrossRefPubMed

27.

Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2009). Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thrombosis Research, 124(5), 588–591. doi:10.1016/j.thromres.2009.06.012.CrossRefPubMed

28.

Ciccarelli, G., Barbato, E., Golino, M., Cimmino, G., Bartunek, J., Di Serafino, L., et al. (2017). Prognostic factors in patients with stemi undergoing primary PCI in the clopidogrel era: role of dual antiplatelet therapy at admission and the smoking paradox on long-term outcome. Journal of Interventional Cardiology, 30(1), 5–15. doi:10.1111/joic.12360.CrossRefPubMed

29.

Gremmel, T., Kopp, C. W., Moertl, D., Seidinger, D., Koppensteiner, R., Panzer, S., et al. (2012). Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thrombosis Research, 129(5), 616–622. doi:10.1016/j.thromres.2011.11.019.CrossRefPubMed

30.

Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2010). Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. Journal of Thrombosis and Haemostasis, 8(1), 37–42. doi:10.1111/j.1538-7836.2009.03644.x.CrossRefPubMed

31.

Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2010). Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart, 96(3), 186–189. doi:10.1136/hrt.2009.171488.CrossRefPubMed

32.

Gremmel, T., Muller, M., Steiner, S., Seidinger, D., Koppensteiner, R., Kopp, C. W., et al. (2013). Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrology, Dialysis, Transplantation, 28(8), 2116–2122. doi:10.1093/ndt/gft103.CrossRefPubMed

33.

Aradi, D., Vorobcsuk, A., Lenkey, Z., Horvath, I. G., & Komocsi, A. (2010). Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets, 21(1), 1–10. doi:10.3109/09537100903391015.CrossRefPubMed

34.

Badr Eslam, R., Lang, I. M., Koppensteiner, R., Calatzis, A., Panzer, S., & Gremmel, T. (2013). Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. International Journal of Cardiology, 168(1), 403–406. doi:10.1016/j.ijcard.2012.09.103.CrossRefPubMed

35.

Gremmel, T., Koppensteiner, R., Ay, C., & Panzer, S. (2014). Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation, 44(3), 319–324. doi:10.1111/eci.12236.CrossRefPubMed

36.

Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2014). In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thrombosis and Haemostasis, 111(3), 474–482. doi:10.1160/TH13-07-0558.CrossRefPubMed

37.

Marjoram, R. J., Voss, B., Pan, Y., Dickeson, S. K., Zutter, M. M., Hamm, H. E., et al. (2009). Suboptimal activation of protease-activated receptors enhances alpha2beta1 integrin-mediated platelet adhesion to collagen. The Journal of Biological Chemistry, 284(50), 34640–34647. doi:10.1074/jbc.M109.020990.CrossRefPubMedPubMedCentral

38.

Clemetson, K. J., & Clemetson, J. M. (2001). Platelet collagen receptors. Thrombosis and Haemostasis, 86(1), 189–197.PubMed

39.

Gremmel, T., Frelinger 3rd, A. L., & Michelson, A. D. (2016). Platelet physiology. Seminars in Thrombosis and Hemostasis, 42(3), 191–204. doi:10.1055/s-0035-1564835.CrossRefPubMed

40.

Clemetson, K. J., & Clemetson, J. M. (2007). Collagen receptors as potential targets for novel anti-platelet agents. Current Pharmaceutical Design, 13(26), 2673–2683.CrossRefPubMed

Title: Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy
Authors: Patricia P. Wadowski
Beate Eichelberger
Christoph W. Kopp
Joseph Pultar
Daniela Seidinger
Renate Koppensteiner
Irene M. Lang
Simon Panzer
Thomas Gremmel
Publication date: 01-08-2017
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 4/2017
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-017-9746-0

2024 ASCO Annual Meeting

Springer Medicine

Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

A Swine Model of Percutaneous Intracoronary Ethanol Induced Acute Myocardial Infarction and Ischemic Mitral Regurgitation

Development and Characterization of a Porcine Mitral Valve Scaffold for Tissue Engineering

Exome Sequencing Identifies Candidate Genetic Modifiers of Syndromic and Familial Thoracic Aortic Aneurysm Severity

Thoracic Aneurysms and Dissections: Towards a Further and Better Knowledge

Severity of Hypertension Correlates with Risk of Thromboembolic Stroke

Various Regulatory Modes for Circadian Rhythmicity and Sexual Dimorphism in the Non-Neuronal Cardiac Cholinergic System